

Drug-coated balloon (Sequent Please Neo) vs drug-eluting stent treatment for acute ST-elevation myocardial infarction: a randomised trial

Submission date 15/07/2025	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 15/07/2025	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 21/04/2026	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

The rapid treatment of patients with an acute heart attack (ST-elevation myocardial infarction [STEMI]) is well established in terms of its significant benefits. This is done using coronary angiography, where a catheter is inserted (usually) through the wrist with local anaesthetic. The catheter is passed up to the heart and a balloon is inflated at the point of the blockage to reopen it. Once the artery is opened, two potential options are available for trying to keep that artery open in the long term. This involves either implanting a drug-eluting stent (DES) or inflating a drug-coated balloon (DCB) at the point of this blockage. Whilst DES have been used for many years, it is now recognised that a significant number (2-4% per year) re-narrow over time and the physical presence of the stent is likely to contribute to this process. Therefore, many operators now use a DCB, which coats the vessel with an anti-proliferative drug to prevent further narrowing but avoids the need for stent implantation. A direct comparison of these two approaches has not been performed. This study will examine the safety and efficacy of DCB versus DES in patients admitted to hospital with a STEMI. The study will use CE-marked DCB and DES devices. All devices used in this clinical investigation will be used in compliance with their approved Instructions for Use and in accordance with standard clinical practice. This study aims to determine if drug-coated balloon treatment of coronary artery blockages during a STEMI (heart attack) provides an equivalent outcome to treatment with a drug-eluting stents (DES). This will be measured by the 1-year target vessel failure, which is a composite of cardiac death, further clinically-driven treatment of the target vessel or a further myocardial infarction (heart attack) caused by the target vessel.

Who can participate?

Patients with a STEMI which requires emergent percutaneous coronary intervention (PCI)

What does the study involve?

Participants are randomly allocated to one of two groups. One group will receive drug-coated balloon (DCB) treatment and the other will receive drug-eluting stent (DES) treatment. All

participants will receive appropriate medications before, during and after their treatment as per current guidelines and operator/hospital approach, and will be discharged according to hospital policies. No changes to their inpatient care are performed. Post-treatment investigations are as per current practice and guidelines, including blood sampling for troponin at 24 hours and assessment of left ventricular function with transthoracic echo before discharge. Written information regarding the study will be provided to the patient post-procedure and consent obtained for further participation before discharge from hospital, usually on day 1. Follow-up in-person examinations will be conducted in accordance with the usual practices of the participating hospital. Additional study-specific follow-ups will be conducted at 30 days, 1 year, 3 years, 5 years and 8 years via telephone and with a review of patient notes as required. During the follow-up telephone appointments, medical and medication history will be collected to assess if any endpoints or adverse events have occurred and the angina index will be assessed via a short questionnaire.

What are the possible benefits and risks of participating?

Both treatments offered are approved products for use within the UK. It is possible that there may be extra benefits to using the drug-coated balloon (DCB), but this will only be established by this study. The major potential benefit of DCB use during STEMI will be the lack of a permanent implant into the coronary vessel, potentially improving the long-term and very long-term clinical course by preventing the risk of stent re-stenosis. Additionally, DCB treatment can allow a shorter duration of antiplatelets, which would reduce the bleeding risk after a STEMI. Were a bypass ever to be indicated, the treated coronary segment could receive a graft, unlike a stented segment. There are no additional research risks.

Where is the study run from?

University Hospital Sussex NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

April 2025 to October 2034

Who is funding the study?

B. Braun Melsungen AG (Germany)

Who is the main contact?

Dr Scott Harfield, scott.harfield@nhs.net

Contact information

Type(s)

Scientific

Contact name

Mr Scott Harfield

Contact details

University Hospitals Sussex NHS Trust

Brighton

United Kingdom

BN2 5BE

+44 (0)127 369 6955

scott.harfield@nhs.net

Type(s)

Scientific

Contact name

Mr John Hildred

Contact details

University Hospitals Sussex NHS Trust
Brighton
United Kingdom
BN2 5BE
+44 (0)1273 696955 Ext: 62756
john.hildred1@nhs.net

Additional identifiers

Integrated Research Application System (IRAS)
356772

Central Portfolio Management System (CPMS)
68120

Study information

Scientific Title

Drug-coated balloon (Sequent Please Neo) vs drug-eluting stent treatment for acute ST-elevation myocardial infarction: a randomised trial

Acronym

DCB STEMI

Study objectives

Primary objectives:

The primary objective of this study is to determine if drug-coated balloon treatment of coronary artery blockages during an ST-segment elevation myocardial infarction (heart attack) provides an equivalent outcome to treatment with drug-eluting stents (DES). This will be measured by the 1-year target vessel failure, which is a composite of cardiac death, further clinically-driven treatment of the target vessel or a further myocardial infarction (heart attack) caused by the target vessel.

Secondary objectives:

To determine if there is a difference in the following factors between patients having drug-eluting stents (DES) or drug-coated balloons (DCB):

1. Pre-discharge LV function
2. Length of stay
3. Bleeding (BARC)
4. Non-cardiac death
5. Freedom from in-hospital composite of cardiovascular mortality, target vessel myocardial infarction, target vessel revascularisation, stroke and BARC 2/3/5 bleeding

6. Acute and subacute vessel closure/stent thrombosis
7. Contrast and radiation dose
8. Procedural time
9. Costs
10. Follow-up at 30 days, 1 year, 3 years and 5 years:
 - 10.1. Target vessel failure
 - 10.2. All-cause mortality
 - 10.3. Non-cardiac mortality
 - 10.4. Revascularisation of non-target vessel
 - 10.5. Patient-oriented ARC-2 composite endpoint (all-cause mortality, any stroke, any MI, any revascularisation)
 - 10.6. Symptom status
 - 10.7. Bleeding event
 - 10.8. Net-clinical benefit: freedom from target vessel failure and bleeding
11. Cost-effectiveness at 5 years

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 24/09/2025, London – Brighton and Sussex REC (-, -, -, United Kingdom; +44 (0)207 104 8140; brightonandsussex.rec@hra.nhs.uk), ref: 25/LO/0630

Primary study design

Interventional

Study design

Randomized; Interventional; Design type: Treatment, Device, Complex Intervention

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute ST-elevation myocardial infarction

Interventions

The study is an investigator-initiated, prospective, open-label, randomised, non-inferiority study.

The study will be conducted across multiple primary angioplasty (heart attack) centres within the UK.

The target population for this study includes adult patients presenting with ST-segment elevation myocardial infarction requiring primary angioplasty treatment.

Pre-procedure examinations, including the collection of medical and medication history, assessment of angina index, and current medication, are conducted in accordance with routine practice.

Patients who are included as part of the emergency consent process will be randomized (1:1) to one of two groups. One group will receive Drug Coated Balloon (DCB) treatment and the other will receive Drug Eluting Stent (DES) treatment.

All participants will receive appropriate medications before, during and after their treatment as per current guidelines and operator/hospital approach, and will be discharged according to hospital policies. No changes to their inpatient care are performed.

Post-treatment investigations are as per current practice and guidelines, including blood sampling for troponin at 24 hours and assessment of left ventricular function with transthoracic echo prior to discharge.

Written information regarding the study will be provided to the patient post-procedure and consent obtained for further participation prior to discharge from hospital, usually on day 1.

Follow-up in-person examinations will be conducted in accordance with the usual practices of the participating hospital. Additional study-specific follow-ups will be conducted at 30 days, 1 year, 3 years, 5 years and 8 years via telephone and with a review of patient notes as required. During the follow-up telephone appointments, medical and medication history will be collected to assess if any endpoints or adverse events have occurred and the angina index will be assessed via a short questionnaire.

The primary endpoint will be examined as intention to treat.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Target vessel failure measured using a composition of cardiac death, target vessel revascularisation and target vessel myocardial infarction at 1 year

Key secondary outcome(s)

1. Pre-discharge LV function, measured using a transthoracic echo at pre-discharge
2. Length of stay, measured using hospital admission duration
3. Bleeding measured using the BARC scale during inpatient admission and follow-up
4. Non-cardiac death, measured using the death certificate and determining non-cardiac death during inpatient admission
5. Acute and subacute vessel closure/stent thrombosis, measured using an angiogram during the inpatient admission
6. Contrast and radiation dose, measured during the procedure
7. Procedural time, measured during the procedure

Measured at follow-up at 30 days, 1 year, 3 years and 5 years:

1. Target vessel failure and presence of reintervention, measured using a composition of cardiac death, target vessel revascularisation and target vessel myocardial infarction during follow-up
2. All-cause mortality measured using COD information on a death certificate
3. Non-cardiac mortality measured using COD information on a death certificate
4. Revascularisation of the non-target vessel measured using an angiogram and PCI to the non-target vessel
5. Net-clinical benefit: freedom from target vessel failure and bleeding measured using the BARC 3-5 bleeding scale

Completion date

01/10/2034

Eligibility

Key inclusion criteria

This trial presents an all-comers design allowing broad inclusion and few exclusion criteria. Specifically, patients can be included if suffering from STEMI, which requires emergent percutaneous coronary intervention (PCI) via the primary angioplasty service. To meet the criteria of a STEMI, patients need to have:

1. Symptoms of myocardial ischemia lasting for ≥ 30 min
2. Definite ECG changes indicating STEMI: ST elevation of >0.1 mV in two contiguous limb leads or ≥ 0.2 mV in two contiguous precordial leads

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

0

Key exclusion criteria

Current exclusion criteria as of 06/01/2026:

1. Previous CABG

Previous exclusion criteria:

1. Prior PCI of the target vessel
2. Previous CABG
3. Recent (<2 months) history of significant bleeding
4. Cardiac arrest requiring intubation before PPCI
5. Known allergy or contraindication for aspirin, clopidogrel, prasugrel, fondaparinux and/or heparin
6. Life expectancy less than 12 months

Date of first enrolment

13/10/2025

Date of final enrolment

01/10/2027

Locations

Countries of recruitment

United Kingdom

England

Scotland

Wales

Study participating centre

University Hospitals Sussex NHS Foundation Trust

Worthing Hospital

Lyndhurst Road

Worthing

England

BN11 2DH

Study participating centre

Norfolk and Norwich University Hospitals NHS Foundation Trust

Colney Lane

Colney

Norwich

England

NR4 7UY

Study participating centre

University Hospitals Dorset NHS Foundation Trust

Management Offices

Poole Hospital

Longfleet Road

Poole

England

BH15 2JB

Study participating centre

Worcestershire Acute Hospitals NHS Trust

Worcestershire Royal Hospital

Charles Hastings Way

Worcester

England

WR5 1DD

Study participating centre

St George's Healthcare Nhs
Blackshaw Road
London
England
SW17 0QT

Study participating centre
Sheffield Teaching Hospitals NHS Foundation Trust
Northern General Hospital
Herries Road
Sheffield
England
S5 7AU

Study participating centre
University Hospitals of North Midlands NHS Trust
Newcastle Road
Stoke-on-trent
England
ST4 6QG

Study participating centre
University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston
Birmingham
England
B15 2GW

Study participating centre
Cardiff & Vale University Lhb
Woodland House
Maes-y-coed Road
Cardiff
Wales
CF14 4HH

Study participating centre
St. Bartholomews Hospital
West Smithfield

London
England
EC1A 7BE

Study participating centre

Portsmouth Hospitals University NHS Trust

Queen Alexandra Hospital
Southwick Hill Road
Cosham
Portsmouth
England
PO6 3LY

Study participating centre

University Hospitals of Derby and Burton NHS Foundation Trust

Royal Derby Hospital
Uttoxeter Road
Derby
England
DE22 3NE

Study participating centre

University Hospitals of Leicester NHS Trust

Leicester Royal Infirmary
Infirmary Square
Leicester
England
LE1 5WW

Study participating centre

The Royal Wolverhampton NHS Trust

New Cross Hospital
Wolverhampton Road
Heath Town
Wolverhampton
England
WV10 0QP

Sponsor information

Organisation

University Hospitals Sussex NHS Foundation Trust

ROR

<https://ror.org/03wvsyq85>

Funder(s)**Funder type**

Industry

Funder Name

B. Braun Melsungen

Alternative Name(s)

B. Braun Melsungen AG

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Germany

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Data sharing statement to be made available at a later date